Scilex Holding Co. (SCLX) Stock Price, Quote & News

Company Profile

Scilex Holding Company focuses on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. Its commercial products include ZTlido (lidocaine topical system) 1.8% (ZTlido), a prescription lidocaine topical product for the relief of neuropathic pain associated with postherpetic neuralgia (PHN), which is a form of post-shingles nerve pain; ELYXYB, a ready-to-use oral solution for the acute treatment of migraine with or without aura...

Industry: Drug Manufacturers - General

Sector: Healthcare

Phone: 650 516 4310

Website: www.scilexholding.com

Address:

960 San Antonio Road, Palo Alto, United States

Sacsofcash Aug. 19 at 5:19 PM

$SCLX looks like we are cooked@ what's your excuses here Henry ?¿? The silence is deafening- shareholders who have been killed deserve some answers. I believe it's either you answer now or in many many court hearings in the near future.

0 · Reply

Sacsofcash Aug. 19 at 4:51 PM

$SCLX near all time lows for year?🥴

0 · Reply

Loonster Aug. 19 at 3:45 PM

$SCLX BITC is on a tear. Bottom is in and massive rally into EOY. Good for SCLX

0 · Reply

GordoHLYK13 Aug. 19 at 2:37 PM

$IGC Bull Case in a nutshell: The patented micro-dose THC + melatonin formulation is the key asset, targeting Alzheimer’s agitation through complementary pathways. IGC retains the rights, so a strong Q4 Phase 2 CALMA readout could dramatically de-risk IGC-AD1 and put the company on the radar for licensing, partnership, or acquisition interest. With a micro-cap valuation, even a $200M–$300M+ re-rating could translate into substantial per-share upside. The key catalyst is simple: statistically significant Phase 2 data = potential institutional interest, short covering, and Big Pharma negotiations. 🔥 The setup is binary: Q4 data is the catalyst. If CALMA hits, $2–$3+ becomes a plausible bull-case scenario—not a guarantee. $LABS $SCLX $GWPH $IGC stands out: Phase 2 CALMA, patented THC + melatonin formulation, and a Q4 2026 readout ahead. Positive THC/CBD data elsewhere only strengthens the cannabinoid-agitation thesis. Don’t underestimate $IGC—this setup could get very interesting. 🔥

0 · Reply

dostephe Aug. 18 at 9:43 PM

$SCLX If Henry Ji invested in GOOG it would somehow put them out of business. The man knows how to destroy shareholder value in a way that would make Enron executives jealous.

0 · Reply

Wellthen Aug. 18 at 5:47 PM

$SCLX Ji is the biggest scam artist ever. Chases every rainbow, mismanages valuable assets, invests in crap, screwed shareholders, stole our money and our trust, yet rewards himself handsomely. THIEF, THIEF, THIEF, THIEF, THIEF, THIEF, THIEF, THIEF, THIEF, THIEF, THIEF, THIEF, THIEF, THIEF, THIEF, THIEF, THIEF, THIEF, THIEF, THIEF, THIEF, THIEF, THIEF, THIEF, THIEF, THIEF, THIEF, THIEF, THIEF, THIEF, THIEF, THIEF, THIEF, THIEF, THIEF, THIEF, THIEF, THIEF, THIEF, THIEF.

0 · Reply